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OBJECTIVE: The recently cloned gene p 16 (aMSTI) has been identified as a putative tumor suppressor
gene that binds to CDK4 and CDK6 (cyclin-dependent kinases), preventing their interaction with cyclin
D I and thereby preventing cell cycle progression at the G1 stage. In addition, the p 1 6 gene has been shown
to have a highfrequency of mutation in some tumor cell lines; however, it has also been shown that a much
lowerfrequency of mutation occurs in primary tumors. This study investigated the mRNVA expression level
and mutation status of the p16 gene in ovarian tumors.
METHODS: We performed quantitative polymerase chain reaction and direct cDJNA sequencing atialysis.
To confirm the p16 protein level in ovarian tumors, Western blotting and immurnohistochiemical staining
were perforied. Expression levels ofmRaZA for the p1 6gene relative to the P-tubulin gene were examined
in 32 ovarian tumors (24 carcinomas, six low malignant potential tumors, and two benign tumors) and six
normal ovanres.
RESULTS: The mRNA expression level ofp16 was significantly elevated in 28 ovarian tumors (22
carcinomas, five low malignant potential tumors, and one benign tumor) compared with that of normal
ovaries. Western blotting analysis and immunohistochemical staining confirmed elevated p16 protein levels
in ovarian tumor samples. Among 32 ovarian tumors, cDNA sequencing of the p16 gene showed no p16
mutation resulting in a coding error, although one silent mutation and three polymorphisms werefound.
CONCLUSIONS: Although p 1 is seldom mutated in ovarian tumors, the overexpressionfofp 16 in moast
ovarian tutmor cases indicates a dysfunction in the regulatory complex for G 1 arrest. Therefore, overexpression,
ofp 16 may be an important early event in the neoplastic tran.sformation of the ovarian epithelium. (J Soc
Gynecol Intest 1997;4:95-102. Copyright 1997 by the Society for Gynecologis Inrestigatioti.)
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T o date, ovarian cancer remains the number one killer
of women with gynecologic cancer. Approximately
75% ofwomen are diagnosed with high-stage (III and
IV) disease. During the past 20 years, neither diagnosis nor
5-year survival have improved greatly. It remains a challenge
to develop new markers to detect early disease and to charac-
tenze biologic modifiers that will down-regulate metastatic
disease.
In light of the potential ofgene therapy, it seems appropriate
to establish a data base to catalog the genetic alterations of
either oncogenes or suppressor genes that might contribute to
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the phenotypic changes necessary to down-regulate tumor
cells. We have initiated a tumor data base including patients
with all grades of ovanan cancer as well as normal ovanies. The
data base is intended to document the genes associated with
signal transduction, cell-cycle, or cell-surface control mecha-
nisms that may be insulted (mutated) or whose expression may
be modified as a result of the transformation process. Such
information may aid the selection of appropriate biologic
modifiers for gene therapy. The data base is presently being
developed by examining the sequence and expression status of
known oncogenes and suppressor genes by isolating mRNA
from fresh frozen specimens and using polymerase chain reac-
tion (PCR) to examine the products derived from cDNA
synthesized from mRNA. We have looked at the expression of
p53 and p21 and sequenced p53 to determine mutations. Our
overall findings corroborate other investigations in that ap-
proxrimately 50% of high-stage tumors have p53 mutations and
underexpress the p21 gene. We have also begun to evaluate
cell-cycle control genes because of their obvious potential in
contributing to the growth of tumors that may or may not
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have a p53 mutation. In recent years, many of the genes in-
volved in cell-cycle control have been identified and cloned,
and the products of these genes have been documented.'-'
Cyclin-dependent kinases, along with their cyclin-specific
counterparts, are responsible primarily for driving the cell cycle
past the GI stage through phosphorvlation of the Rb protein.5
Once retinoblastoma protein is phosphorylated, it releases the
transcription factor E2F, which is required for progression
from G' to the S phase of the cell cycle.6 There also exists a
series of suppressors of cell division, which includes p21, pI6,
p15, and p107.24 Among these suppressors, p16 has been
documented as frequently mutated in many cell lines, presum-
ably producing a dysfunctional p16 protein product, which
cannot inhibit the CDK4 and CDK6 kinase reaction.7 9 More
recently, in a senies of primary tumors, it has been established
that relatively few specimens had documentable mutations in
p16. '1-2 In this report, we examine the expression and mu-
tational status of the p16 gene in ovarian carcinoma with re-
gard to both type and stage of disease.
MATERIALS AND METHODS
Tissue Samples
Ovarian epithelial tumor samples were obtained from 32 pa-
tients. The series consisted of cwo cases of benign cystadeno-
mas, six cases of cystadenomas of low malignant potential, and
24 cases of cystadenocarcinomas. The clinical stage of all tu-
mors was classified using the International Federation of Gy-
necology and Obstetnics criteria. Normal ovaries were ob-
tained from six patients who underwent surgery for benign
gynecologic disease. The tissue samples were obtained imme-
diately after the surgical procedure and were flozen in liquid
nitrogen and stored at -800°.
mnRNA Isolation and cDNA Synthesis
Extraction ofmRNA from the tissue samples and complemen-
tary DNA synthesis were performed according to the methods
we described previously.ii Briefly, mRNA was isolated by
using a RiboSep mRNA isolation kit (Becton Dickinson
Labware). In this procedure. poly A+ mRNA was isolated
directly from the tissue lysate using the affinity chromatogra-
phy medium Oh1go (dT) Cellulose. The amount of niRNA
recovered was quantified by ultraviolet spectrophotometry.
The cDNA was synthesized with 5.0 pug ofmRNA by random
hexamer priming using the 1st strand cDNA synthesis kit
(Clontech). The efficiency of cDNA synthesis was estimated
by using a glyceraldehyde-3-phosphate dehydrogenase-
positive control amplifier (Clontech).
Quantitative PCR and Primer Sequences
Quantitative PCR was performed according to the method
of Noonan et al'4 with some modifications. The primer
sequences used in this study were designed according to
the cDNA sequences described by Serrano et al,7 Hall et al,'
and Okamoto et al.'" For Quantitative PCR: p16 sense
primer, 5-CCCCACTACCGTAAATG-3; p16 antisense
primer, 5-GAGCTTTGGTTCTGC(CA-3; P-tubulin sense
pnrmer, 5-TGCATTGACAACGAGGC-3; and f3-tubulin an-
tisense primer, 5-CTGTCTTGACATTGTTG-3. For cDNA
Sequencing: p16 1A sense primer, 5-CGCACCGAATAGT-
TACG-3; p16 1B antisense primer, 5-CCAGCGTGTC-
CAGGAAG-3; p16 2A sense primer, 5-CTTCCTGGACAC-
GCTGG-3; and p16 2B antisense primer, 5-CTGTAG-
GACCTTCGGTG-3. Pairs of the primers were designed to
include at least one intron-exon splice site in the correspond-
ing genomic sequence to eliminate amplification from geno-
1mac DNA. The PCR reaction mixture consisted of cDNA
derived from 50 ng ofmRNA, 5 pmol of sense and antisense
primers for both the target gene and the P-tubulin gene, 200
ixmol of dNTPs, 5 pLCi of [a-32PI dCTP, and 0.25 U of Taq
DNA polymerase with reaction buffer (Promega) in a final
volume of 25 p.L. The target sequences were amplified in
parallel with the j3-tubulin gene as an internal control. Thirty
cycles of PCR were carnred out in a thermal cycler (Perkin-
Elmer Cetus). Each cycle of PCR included 30 seconds of
denaturation at 950C, 1 minute of printer annealing at 620C,
and 1 minute of extension at 720C.
The products were separated on a 2% agarose gel, and the
radioactivity of each band was determined using a Phospho
Imager (Molecular Dynamics).
Direct cDNA Sequencing
To prepare the template DNA for the sequencing reaction, we
performed PCR with the amplification primers as described
earlier. The p16 cDNA was sequenced from codon 40 to the
terminal amino acid, covering from the middle of exon 1
through the end of exon 3. Amplified cDNA samples were
purified using Wizard PCR Preps DNA purification system
(Promega). The sequencing reaction was carried out using a
PRISM Ready Reaction DveDeoxy Terminator Cycle Se-
quencing Kit (Applied Biosysterns). To remove excess DyeDe-
oxy, spin columns were used (Princeton Separation). An ap-
plied Biosystems Model 373A DNA Sequencing System was
used for direct cDNA sequence determination.
Western Blotting
A protein lysate was prepared fronm 0.5 g of frozen tissue pul-
verized under liquid nitrogen. We added to the tissue 0.5 mL
of 2 X sodium dodecylsulfate (SDS) sample buffer (62.5
mnol/L Tris-HCl, pH 6.8, 4% SDS, ).01% glycerol, 0.05o%
2-p-mercaptoethanol, and 0.05% bromiophenol blue) contain-
ing 10 prmol/L phenylarsine oxide, 2 mnmol/L sodium ortho-
vanadate, 1.3 mmol/L ethyleneglycol-bis-(P-aminoethyl-
ether)-N, N. N', N'-tetra-acetic acid, and 100 p. mol/L tri-
fluoperazine. The sanriple was placed in a boiling water bath for
5 nirutes and thereafter was centrifuged at I10,1)00 rpm for 10
minutes. The supernatant at 50 ptg protein/lane Was used for
electrophoresis on a 13% SDS polvacrvlamide gel.
Proteins were transferred electrophoreticaily to PVDF
niembranes (Bio-Rad) for 220 hours at 3Al V. Membranes were
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blocked with nonfat milk, incubated with 4 ug/nmL punified
anti-human p1l6NK4 monoclonal antibody (Pharmingen) for 3
hours, incubated with goat anti-mouse IgG( horseradish per-
oxidase complex (Bio-Rad), and developed with horseradish
peroxidase color development reagent (Bio-Rad).
Immunohistochemistry
Irnmunohistochemical staining was performed using a Vec-
tastain Elite ABC kit (Vector). Formalin-fixed and paraffin-
embedded specimens were routinely deparaffinized and incu-
bated in methanol with 0.3% HO, for 30 minutes at room
temperature to block endogenous peroxidase activity. After
treatment, the samples were incubated with 10 pug/mL puri-
fied anti-human p6liNK4 monoclonal antibody (Pharmagen)
for 18 hours at 40C in a moisture chamber, incubated with
biotinylated anti-mouse IgG (Vector) for 30) minutes at room
temperature, and thereafter incubated with ABC reagent (Vec-
tor) for 30 minutes at room temperature. The final products
were visualized by using diaminobenzidine (0.2 nmg/inL) in the
presence of 0.003% HO,, and sections were counterstailied
with 1% methyl green before clearing and mounting. Negative
controls were performed by substituting nonimniune serum
for the primary antibody.
RESULTS
Quantitative PCR of p16 Expression
To determine the number of PCR cycles appropriate for
quantification, we monitored PCR amplification from cycle
15 through cycle 35 everv five cycles. Linearity of the (3-tu-
bulin gene and p16 gene PCR products was consistent over 30
cycles (Figure 1), and therefore 30 cycles of PCR was used
routinely for expression of the p16 gene.
To compare the expression of p16 in normial and ovarian
carcinoma tissues, we performed PCR amplification using a
(-tubulin internal standard.13 Oligonucleotide primers used
for co-amplification of pl 6 and (3-tubulin are given in Mate-
rials and Methods. Several genes were tested as internal con-
trols. and (3-tubulin was the most satisfactory. Actin was found
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Figure 1. Linealrity of the (3-tubulin and the p1I6 polyinerase chain








NORMAL BENIGN LMP CANCER
Figure 2. Expression of p16 relative to P-tubulin (ratio of p16/(3-
tubulin) in normal ovary, benign ovanian tumor, low malignant po-
tential (LMP) tumor, and ovarian cancer. Expression of p16 is sig-
nificantly elevated in many ovarian tumor cases.
not used for this reason. Glyceraldehyde 3-phosphate dehy-
drogenase was consistently expressed. but was so highly ex-
pressed relative to most genes that relative expression deter-
minations were difficult for genes ofaverage or low expression.
Beta-tubulin was found to be the nmost consistently expressed
in normal and carcinomatous tissues and was not so highly
expressed as to compromise the evaluation of comparison
genes of low or average expression.
We examined the relative expression of the p16 gene from
six normal ovarian tissues, two benig-n adenomnas, six adenomas
of low malignant potential, and 24 ovarian carcinomas (Figure
2). The relative expression of plf6 to 3-tubulin was elevated in
most ovarian tumnors (28 of 32 or 88'i compared with normal
ovaries). Expression of pl 6 in most tumors (26 of 32. 81%) wvas
four or more standard deviations above the mean for the nor-





Figure 3. p16 and P-tubulin PCR products froi normal ovary and
ovarian cancer. Case 4, case 3, and case 6 are normal ovaries. Case 1t9,
case 26, case 23. and case 29 are ovarian cancers. Expression of p16
relative to (-tubuhlin is higher in cancer sallples than in normal ova-
ries.
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Nornal ovary 6 0
Benign tumor 2 1 (50%)
Low malignant potential 6 5 (8300)
Carcinoma 24 22 (92%)
Stage
Il-l 4 3 (75%)
IlI-IV 20 19 (95%)
Type
Serous 17 15 (88%)
Otherst 7 7 (100%)
* Overexpression = +2 SD or greater over the mean normal values.
including endometrioid, clear-cell, and mucinous.
mal ovary. Figure 3 compares pi6 expression in normal ovar-
ian tissue versus ovarian carcinoma. Five of six low malignant
potential tumors (83%) and 22 of24 carcinomas (92%) showed
overexpression (Table 1). With respect to clinical stage of dis-
ease, three of four (75%) stage I-II carcinomas and 19 of 20
(95%) stage lll-IV carcinomas showved significant p16 mRNA
elevation (Table 1). One of the two benign adenomas exam-
ined also exhibited p16 overexpression. Normal levels of p16
were found in only one adenoma, one mucinous adenoma of
low malignant potential, and two serous carcinomas.
p16 Mutations
To determine whether the overexpression of p16 could be
related to mutation resulting in dysfunction of the cell-cycle
inhibitor, we sequenced the PCR-amplified products of the
p16 gene for all 38 specimens. The p16 gene was amplified
using two sets of primers (see Materials and Methods) that
extended from the middle of exon 1 (amino acid 40) through
the end of exon 3. This area encompasses the known muta-
tions already described for p1 6. No mutations were discovered
in the six normal specimens. Four sequence alterations were
discovered in the 32 tumor specimens (Table 2). A benign
tumor (case 8) showed a G to T transversion in codon 127,
which has previously been described as a polymorphism."I
One tumor oflow malignant potential (case 9) and one o anian
cancer (case 24) showed the same G to A transition in codon
148, a known polymorphismi10" One low malignant po-
tential tumor (case 12) showed a G to A transition in codon 68.
This base change, however, does not alter the amino acid
sequence of the p16 protein. Overexpression of p16 and base
alteration data are summanized in Table 3, indicating an over-
expression rate of 88% (28 of 32) in ovarian tumors with four
cases of base alteration, including three known polymorphisms
and one mutation without an amino acid sequence change.
Western Blot p16 Expression
To confirm that p16 mRNA overexpression results in an ac-
tual accumulation of the p1 6 protein, two tumor cases that had
demonstrated overexpression of p16 mRRNA were examined
by companing them with normal ovarian tissue by Western
blot. Both samples showed overexpression of p16 protein
compared with normal ovarian tissue. In Figure 4, tumor p16
protein extracted from case 27 (lane 2) is compared with ex-
tracts from normal tissue (lane 1) and Hela cell (lane 3), known
to overexpress the p16 protein. The second band of higher
molecular weight noted in the Western blot (lanes 2-3) has
been identified as a cross-reacting protein with the p16 anti-
body and is found only in tumor extracts associated with p16
overexpression.
Immunohistochemistry
To confirm that p1 6 overexpression was actually occurring in
tumor cells and not in the underlying stromal or vascular tissue,
we also examined p16 expression using immunohistochemical
staining of paraffin-embedded, fornialin-fixed sections of nor-
mal ovary and ovarian carcinoma (Table 4). Five nonnal ovar-
ian tissues, four low malignant potential tumors, and 15 car-
cinomas were examined using immunohistochemistry. All four
of the low malignant potential tumors and 14 of 15 of the
carcinomas showed increased staining for p16 (Figure 5C, D).
One clear-cell carcinoma had a weak positive staining similar
in intensity to that detected in two of the five normal ovarian
epithelial specimens (Figure 5A, B). A comparison of pl6 ex-
pression examined by both quantitative PCR and immuno-
histochemistry confirms the efficacy of both approaches in
demonstrating the overexpression of p16 in both low malig-
nant potential and invasive ovarian carcinomas (Table 5).
DISCUSSION
It is noxv evident that the progression of cells through the cell
cycle is regulated by positive signals (cyclins and cyclin-
dependent kinases) and negative signals (cyclin-dependent ki-
nase inhibitors such as p2l and p16). -4 Thus, p16 binds to
CDK4/6 and inhibits the catalytic activity of cyclinD!
Table 2. Ovarian Tumors With p16 Base* Alterations
Case
no. Tumor type Exon Codon Base change Amino acid change
8 S Cvstadenioma 2 aa127t GCA-TCA Ala-Ser
9 S Cystadenonma (LMP) 2 a 148: GCG-ACG Ala-Thr
12 M Cstadenonia (LMP) 2 aa68 GCG-GCA Ala-Ala
24 S Carcinoma aa 48- GCG-ACG Ala-Thr
s=ertus. M = tinUCitno. LNIP - los naigait poteltial
* Four base chances in 32 ovarian tumors were observed. Three are known polymorphisms; one base change in codon 68 did not alter the original amino acid.
tC-J traosversioti it coilon 12 has been decribed as polstorphisuit.
G-t-(A transition in cidwii 1.48 has been described as polyniorphis'll
98 J Soc Gynecol Invest Vol. 4, No. 2, Mar./Apr. 1997 Shigemasa et al
p16 Overexpression in Ovarian Cancer J Soc Gynecol Invest Vol. 4, No. 2, Mar./Apr. 1997 99
Table 3. Expression and Mutation Analysis of p16 Genes in Normal Ovaries and Ovarian Tumors
Case Histologic Stage! Lymph node pl6































































































































































N normlai ovars. WT wild tipe; SA = serros.wide' oii; P01 = polysnorphimL LMIP = loxv iagliplant poencrial; NJ=N not identified: MA
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International Federation of Gynecology and Obstetrics stage and histologic grade.








































CDK4/6 complex, shich controls cell passage through the G1
phase of the cell cycle by phosphorylation of the retinoblasto-
ma protein (Figure 6). In this manner, p16 could act as a tumor
suppressor gene. Conflicting results have been reported con-
cerning the frequency of p16 mutations. It has been reported
that p16 homozygous deletions were found frequentlyv in cell
lines derived from a wide variety of human tumors, including
lung, breast, brain, skin, bladder, kidnev, and ovary, as well as
in leukemia aInd nielanoma.-" However, it has also been re-
ported that the frequency of intragenic p16 nsutations was
quite low in primary tumor samples of lung, brain, bladder,
kidney, ovarn, liver, colon, and head and neck- (l With
respect to ovarian tumnors, Kamb et a]8 reported p16 deletions
in two of seven lesions. However, Okanmoto et a1'fi found only
one p16 mutation amoing 18 primary ovarian tumrors.
In the present study, the results obtained for p16 expression





Figure 4. Western blot analvsis of p16 protein. Lane I = normal
ovary. Lane 2 = ovanan cancer case 27, which showed pl6 mRNA
oxerexpression. Lane 3 = Hela cell line as positive control. The p16
protein is strongly positive in the ovariani arc inoma sample and the
Hela cell fic. buit is nec anve in the normal ovary sample.
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I ^U^ J o c Ie Vo. 4, No. - M r 9
Table 4. Imniunohistochemistry: Expression of p16 Protein in




Normal ovary N +
Normal ovary N +
Normal ovary N -
Serous LMP 2+ 2+
Mucinous LMP 4+ 2+
Mucinous LMP 4+ 2+
Mucinous LMP N 2+
Serous carcinoma 4+ 2+
Serous carcinoma N 2+
Serous carcinoma N 2+
Serous carcinoma 4+ 2+
Serous carcinoma 4+ 2+
Serous carcinoma 4+ 2+
Serous carcinoma 4+ 2+
Serous carcinoma 4+ 2+
Serous carcinoirra 4+ 2+
Serous carcinoma 4+ 2+
Mucinous carcinoma 4+ 2-
Mucinous carcinooma 4+
Mucinous carcinoma 4+ 2+
Endometnoid carcinoma 44 2+
Clear-cell carcinorna 4+ +
N normal; L[Nil' = los iialignant porstial
* mRNA expression of p16 (see Table 3).
+ = vse wa.k ositive stlnoring on the siurfce of epithellal cells. 2+ strong sta3iir g
in more than SiAot iltlior crli,
A
Table 5. Comparison of p16 Expression by Quantitative
Polvnmcrase Chain Reaction and Immunohistocheniistry in Nonwil
Ovary and Ovarian Cancer
mRNA Protein
Disease N Overexpression expression
Normal 6 0)/6 0/5*
Benign 2 1 /
Low malignant potential 6 5/6 4/4
Carcinoma 24 22/24 14/15t
* Two cases showed weak staining on the surface epithelium_
t One case showed weak stainintg in less trasi ii of tunlor cells.
age (approximately 90%) of high-stage carcinomas appeared to
overexpress the pl6 gene as assessed by quantitative PCR and
confirmed in selected cases by both Western blot and immnu-
nohistochemistry. These data therefore suggest not only that
muRNA is overexpressed, but also that this is translated effec-
tively into a p16 product that presumably accumulates in the
cytoplasm of carcinoma cells. Furthermore, sequencing of the
p16 gene from this series of tumors demonstrates that no al-
teration in amino acids occurred, and therefore the protein
product of this overexpressed mRNA g>ene is a putatively
functional wild-type product that presumiably has the capacity
to bind to CI)K4 and CD)K6. Such a situation, of course, is
paradoxical because these malignant carcinomas are highly
proliferative and obviously freely and frequently pass through
the cell cycle without regard to the regulatory capacity of this
B ,S, $ ADIII
Figure 5. Ilmmunohistochenmistry. A) p16 is negative on the nonmal osarian surface epithelium. B) Very weak pIG positive staining is observed
on the part of the surface epithelicLins of nornmal ovar-s. CD) p16 Is strongly positive in the cytoplasim of cancer cells.
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Figure 6. Cyclin D and CD)K4/6 stimulate cell division by phos-
phorylating Rb (retinoblastonia) protein. A transcription factor such
as E2F is released and activates the transinon from G1 to S phase. p16
binds to the catalytic submit CDK4 or CD)K6 and inactivates the
cvclin D)-CDK4/6 complex. E2F released from Rb nmay also activate
the transcription of pl6.
overexpressed p16 protein. Although the obvious conclusion
might have been that p16 was mutated, this was not the case.
As such, the data point to some downstream dysfunction that
allows continued cell-cycle progression without regulation.
Several potential candidates may be suggested for this down-
stream dysfunction, which would allow constitutive cell cv-
cling in the face of overexpressed levels of p16 (Figure 6).
They are as follows: 1) a defect in the cyclin-dependent kinase
that would prevent p16 binding and therefore down-
regulation; 2) the activation of an alternate pathway to phos-
phorylate the Rb protein and therefore bypass pl6 regulation;
3) a defect in the Rb protein that allows it to be constitutively
active and therefore not regulatable: 4) an incapacitated phos-
phatase that allows continued activits of the Rb protein due to
its hyperphosphorylation and the loss of capacity to be dephos-
phorylated and reassociated with E2F, 5) a defect in the Rb or
E22F transcription factor that wvould not allow dimerization of
the hypophosphorvlated form and therefore inactivation of the
complex: 6) an endogenous binding protein that inactivates
p16 and prevents it from binding to CI)K2 and CDK4; or 7)
overexpression of cyclin 1D and CDK4 and CDK6, which
would override and outperform the inhibitory effects of the
high levels of p16 present. It should be pointed out that al-
though the predominant observation was overexpression of
p16 in most tumors. there were three tumors that did not
overexpress the p<16 gene: these suggest the existence of an-
other matrix of genetic insults that may be implicated in ovar-
ian cancer. At present, there are no data to SuLggest what this
combination of insults might be. but it is possible that some
small group of the tumors do not include the phenomenon of
p16 overexpressionl.
Although there may be insufficient data to conclude that
p16 dysfunction is an early consequence in the transformation
process, and may actually precede it. such an indication may be
possible. It could be viewed as an early loss of cell-cycle con-
trol, which would allow low malignant potential growth or
benign growth and therefore could be a contributing factor to
the downstream potential for metastatic and pervasive growth.
The data indicated overexpression in most low malignant po-
tential tumors and in one of two benign tumors. Clearly, fur-
ther evaluation and a more extensive study in this area are
warranted. Loss of control of the cell cycle at the G1 interface
through lack of control of p-16 appears to precede the muta-
tions that occur in p53, resulting in underexpression ofp21 and
subsequent loss of control of the cell cycle. More recently, the
p15 gene, a close relative of p16, has also been described,
although its role in ovarian carcinoma is still unclear.1-5 In
addition, hypermethylation of the p 16 gene in CPG islands has
been demonstrated as contributing to the reduced expression
of this gene, and therefore hyponmethylation may be a factor in
the overexpression noted here. "' Because pl6 is overexpressed
in most ovarian tumors-both low malignant potential and
high-grade disease-there is no obvious correlation between
p 1 6 overexpression and p53 mutation or p21 underexpression.
Overexpression of p16 is both an earlier event in the devel-
opment of these ovarian carcinomas and is manifest in a much
higher percentage of tumors than is p53 mutation or p21 L1i-
derexpression. To clarify this paradox. we will continue to
evaluate the downstream factors already mentioned in this dis-
cussion in an attempt to elucidate the relations between a
dysfunctional cell-cycle control system and overexpression of
p16 in ovarian carcinoma.
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